Donor-derived fulminant herpes simplex virus hepatitis after liver transplantation: Two cases and review of literature.


Journal

Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688

Informations de publication

Date de publication:
Aug 2023
Historique:
revised: 12 05 2023
received: 18 04 2023
accepted: 16 05 2023
medline: 15 8 2023
pubmed: 29 5 2023
entrez: 29 5 2023
Statut: ppublish

Résumé

Fulminant herpetic hepatitis due to herpes simplex virus (HSV), serotype 1 or 2, is a rare but often fatal complication after solid organ transplantation (SOT). HSV hepatitis in SOT recipients can occur either due to primary infection acquired post transplantation, viral reactivation in a seropositive patient, or as donor-derived infection. Cases of fatal hepatitis have been reported in the liver as well as in other SOT recipients. The fatal outcome is mostly due to delayed diagnosis and treatment, which is explained by the lack of clinical specificity of HSV hepatitis. We report two cases of fatal donor-derived HSV hepatitis in liver-transplanted recipients. We reviewed all published cases of donor-derived HSV infections after SOT with an evaluation of the presence of prophylaxis and outcome. In both liver recipients, the retrospective determination of HSV serostatus was negative, and both cases occurred in the absence of cytomegalovirus or HSV prophylaxis. A review of the literature showed a significant series of cases of severe hepatitis, mostly fatal, as well as the absence of specific preventive therapy guidelines in cases of HSV serology mismatch. The occurrence of two fatal donor-derived hepatitis made the Swiss Transplant Infectious Diseases working group modify its national recommendations regarding pretransplant serostatus determination and HSV prophylaxis after liver transplantation. Further studies are needed to assess this approach.

Sections du résumé

BACKGROUND BACKGROUND
Fulminant herpetic hepatitis due to herpes simplex virus (HSV), serotype 1 or 2, is a rare but often fatal complication after solid organ transplantation (SOT). HSV hepatitis in SOT recipients can occur either due to primary infection acquired post transplantation, viral reactivation in a seropositive patient, or as donor-derived infection. Cases of fatal hepatitis have been reported in the liver as well as in other SOT recipients. The fatal outcome is mostly due to delayed diagnosis and treatment, which is explained by the lack of clinical specificity of HSV hepatitis.
METHODS METHODS
We report two cases of fatal donor-derived HSV hepatitis in liver-transplanted recipients. We reviewed all published cases of donor-derived HSV infections after SOT with an evaluation of the presence of prophylaxis and outcome.
RESULTS RESULTS
In both liver recipients, the retrospective determination of HSV serostatus was negative, and both cases occurred in the absence of cytomegalovirus or HSV prophylaxis. A review of the literature showed a significant series of cases of severe hepatitis, mostly fatal, as well as the absence of specific preventive therapy guidelines in cases of HSV serology mismatch.
CONCLUSIONS CONCLUSIONS
The occurrence of two fatal donor-derived hepatitis made the Swiss Transplant Infectious Diseases working group modify its national recommendations regarding pretransplant serostatus determination and HSV prophylaxis after liver transplantation. Further studies are needed to assess this approach.

Identifiants

pubmed: 37247223
doi: 10.1111/tid.14080
doi:

Types de publication

Review Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14080

Informations de copyright

© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.

Références

Norvell JP, Blei AT, Jovanovic BD, Levitsky J. Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl. 2007;13(10):1428-1434.
Arana C, Cofan F, Ruiz P, et al. Primary herpes simplex virus type 1 infection with acute liver failure in solid organ transplantation: report of three cases and review. IDCases. 2022;28:e01485.
Wolfe CR, Ison MG. Donor-derived infections: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13547.
Macesic N, Abbott IJ, Kaye M, et al. Herpes simplex virus-2 transmission following solid organ transplantation: donor-derived infection and transplantation from prior organ recipients. Transpl Infect Dis. 2017;19(5):e12739.
Côté-Daigneault J, Carrier FM, Toledano K, Wartelle-Bladu C, Willems B. Herpes simplex hepatitis after liver transplantation: case report and literature review. Transpl Infect Dis. 2014;16(1):130-134.
Thurman RH, König K, Watkins A, Weerasiri T, Permezel M. Fulminant herpes simplex virus hepatic failure in pregnancy requiring liver transplantation. Aust N Z J Obstet Gynaecol. 2010;50(5):492-494.
Lee DH, Zuckerman RA. Herpes simplex virus infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13526.
Longerich T, Eisenbach C, Penzel R, et al. Recurrent herpes simplex virus hepatitis after liver retransplantation despite acyclovir therapy. Liver Transpl. 2005;11(10):1289-1294.
Wendon J, Cordoba J, Dhawan A, et al. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017;66(5):1047-1081.
Tan EX, Wang MX, Pang J, Lee GH. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review. World J Gastroenterol. 2020;26(2):219-245.
Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64(1):69-78.
Holt EW, Guy J, Gordon SM, et al. Acute liver failure caused by herpes simplex virus in a pregnant patient: is there a potential role for therapeutic plasma exchange? J Clin Apher. 2013;28(6):426-429.
Chávez SM, Poniachik JM, Urzua ÁM, et al. Acute liver failure due to herpes simplex virus: diagnostic clues and potential role of plasmapheresis: a case report. Medicine (Baltimore). 2021;100(35):e27139.
Martin-Gandul C, Stampf S, Héquet D, et al. Preventive strategies against cytomegalovirus and incidence of α-herpesvirus infections in solid organ transplant recipients: a nationwide cohort study. Am J Transplant. 2017;17(7):1813-1822.
Chemaitelly H, Nagelkerke N, Omori R, Abu-Raddad LJ. Characterizing herpes simplex virus type 1 and type 2 seroprevalence declines and epidemiological association in the United States. PLoS One. 2019;14(6):e0214151.

Auteurs

Ilana Reinhold (I)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Laurent Teasca (L)

Service of Transplantation, University Hospitals Geneva, Geneva, Switzerland.

Elena Requejo Rodriguez (ER)

Service of Clinical Pathology, University Hospitals Geneva, Geneva, Switzerland.

Thierry Berney (T)

Service of Transplantation, University Hospitals Geneva, Geneva, Switzerland.

Nicolas J Mueller (NJ)

Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.

Matthias Hilty (M)

Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland.

Rea Andermatt (R)

Institute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland.

Francesca Saro (F)

Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.

Philipp Dutkowski (P)

Swiss HPB and Transplantation Center, Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland.

Beat Müllhaupt (B)

Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.

Christian van Delden (C)

Service of Transplantation, University Hospitals Geneva, Geneva, Switzerland.
Transplant Infectious Diseases Unit, University Hospitals Geneva, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH